Regulation of Bone Formation in Renal Osteodystrophy

Status Completed

Clinical Trial Summary

To examine the effects of two types of active vitamin D (calcitriol and doxercalciferol) and two phosphate binders (sevelamer and calcium carbonate) on the bone disease and blood tests of children with kidney failure

Clinical Trial Description

Pediatric patients treated with CCPD who displayed biochemical and bone biopsy proven secondary hyperparathyroidism were randomly assigned to one of 2 vitamin D analogues (calcitriol or doxercalciferol) and one of two phosphate binders (sevelamer or calcium carbonate) in a two by two factorial designed prospective trial. Serum biochemical measurements were obtained at baseline and monthly throughout the 8 months of the trial. Bone biopsy was obtaine at baseline and repeated at study completion. ;

Study Design

Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00560300
Study type	Interventional
Source	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Contact
Status	Completed
Phase	Phase 2
Start date	November 2000
Completion date	November 2006

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02549417` - Phase 3 Study of KHK7580	Phase 3
Completed	`NCT02549404` - Phase 3 Study of KHK7580	Phase 3
Not yet recruiting	`NCT02536287` - Comparison of Total Parathyroidectomy With and Without Autotransplantation	Phase 3
Completed	`NCT02549391` - Phase 3 Study of KHK7580	Phase 2/Phase 3
Active, not recruiting	`NCT03023748` - Intravenous Paricalcitol in Chronic Hemodialysis Patients	Phase 4
Withdrawn	`NCT01426724` - Effects of Vitamin D on Renal Blood Flow, Proteinuria and Inflammation in Patients With Chronic Kidney Disease	N/A
Completed	`NCT01101113` - Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level	Phase 4
Completed	`NCT01220050` - Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary Hyperparathyroidism	Phase 2
Completed	`NCT00537979` - Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis	Phase 4
Completed	`NCT00431496` - A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD)	Phase 4
Completed	`NCT00379899` - ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis	Phase 4
Completed	`NCT00117052` - SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism	Phase 3
Completed	`NCT00073710` - Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium	Phase 4
Completed	`NCT03626948` - SK-1403 Long-term Treatment Study; Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis	Phase 3
Completed	`NCT01382212` - A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis	Phase 3
Completed	`NCT01219855` - Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)	Phase 2/Phase 3
Completed	`NCT01224782` - Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT)	N/A
Completed	`NCT00999037` - FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease	N/A
Completed	`NCT00990704` - Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism	Phase 2
Completed	`NCT00742716` - Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease	Phase 2